Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals

Among Four Key Aspects That Will Underpin US Generics Business In 2021

 
• By David Wallace
  
Four Cogs Hands Sunset
Four key “moving pieces” will influence the success of Hikma’s US generics business in 2021 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business